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ABSTRACT

Separate groups of rats were trained to discriminate the
narcotic agonist-antagonist, cyclazocine (1.25 mg/kg), from
saline or the pure narcotic agonist, morphine (10 mg/kg),
from saline.

In the cyclazocine discriminating animals,

the interoceptive stimuli produced by cyclazocine were found
to be dose related and largely based on central opiate systems in that these effects were reversed by the narcotic antagonist, naloxone.

The discriminative stimulus produced by

cyclazocine was found to be completely generalized to nalorphine, ethylketocyclazocine, pentazocine and morphine while
a lesser degree of generalization was seen to the experimental compounds, U-49,274A and U-50,788E.

The cyclazocine

discriminative stimulus did not generalize to apomorphine,
d-amphetamine, haloperidol, d-butaclamol, 1-butaclamol, clonidine, desipramine, amitriptyline, aceperone and butorphanol.
Cyclazocine generalization to morphine was completely antagonized by naloxone at a dose one-twentieth that required to
antagonize the cyclazocine discriminative stimulus itself.
At no dose tested did naloxone completely antagonize cyclazocine generalization to nalorphine.

A possible dopaminergic

component of the cyclazocine discriminative stimulus was
demonstrated by attenuation of stimulus strength with the
neuroleptics haloperidol, benperidol and d-butaclamol.
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The discriminative stimulus produced by morphine was also
found to be a dose related effect based upon central opiate
mechanisms as demonstrated by naloxone reversibility.

The

discriminative stimulus produced by morphine only partially
generalized to cyclazocine and ethylketocyclazocine.

Nalox-

one antagonized the generalization of morphine to cyclazocine but at a dose four times that required to antagonize
the morphine discriminative stimulus itself.

A possible dop-

aminergic component of the morphine discriminative stimulus
was demonstrated by haloperidol attenuation of stimulus
strength.
Cyclazocine analgesia, demonstrated using the mouse tail
flick procedure, was found to be maximal approximately five
minutes following cyclazocine administration.
sic potency was also

~easurable

Some analge-

35 minutes post cyclazocine.

The analgesic effects of cyclazocine were found to be reversed by naloxone.

Pretreatment with the neuroleptics oxi-

peromide, clozapine and dexclamol before cyclazocine was
found to enhance the analgesic potency of cyclazocine.

iii
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I.

INTRODUCTION

Cyclazocine is a narcotic agonist-antagonist of the benzomorphan series which was first synthesized in the 1950s as
part of a search for a nonaddicting narcotic analgesic.

Cy-

clazocine possesses narcotic agonistic activity and acts as
an antagonist to many of the actions of morphine and other
narcotic agonists.

Based on its agonist activity, cyclazo-

cine was considered of substantial clinical potential as an
analgesic.

Early clinical trials revealed that the analge-

sic potency of cyclazocine far surpassed that of morphine in
post operative patients (Lasagna, et al., 1964).

In addition,

cyclazocine does not produce the euphoria which is observed
following morphine administration, an effect which is believed to be the basis of narcotic addiction (Eddy et al.,
1970).

As a result, cyclazocine is considered to be of low

abuse potential

(Martin~~

al., 1965).

Despite these desirable properties, clinical use of cyclazocine has been very limited due to the severity of the
psychotomimetic effects which it produces
1966; Haertzen, 1970).

(Martin~~

al.,

These effects have been described as

drunkenness, tiredness, anxiety and hallucinations.

The

neurobiological basis of these effects is unknown.
In order to experimentally evaLuate the subjective effects produced by drugs, the behavioral paradigm of drug

2

discrirr.ination has been utilized in which food reinforcement
is delivered to experimental animals based upon responses
made on one of two levers.

The lever on which responses are

reinforced is determined by the injection given before responding commences.

Results from such experimentation using

narcotic drugs has shown that there is a high correlation between the discriminative properties of these drugs in laboratory rats and the subjective effects reported in humans
(for review see Lal et al., 1977; Colpaert, 1977).
Recently, cyclazocine has been shown to produce a discriminative stimulus (Hirschhorn, 1977; Rosecrans et al.,
1978; Schaefer and Holtzman, 1978; Teal and Holtzman, 1980);
however, the mechanism of this action of cyclazocine is unknown.

Further experimentation dealing with the discrimina-

tive stimulus produced by cyclazocine is needed in order
that the basis of the psychotomimetic effects might be determined.

The present set of experiments was undertaken to in-

vestigate the nature of the discriminative stimulus produced
by cyclazocine.

Animals have been trained to discriminate

cyclazocine from saline.

They were then tested for generali-

zation to selected narcotic agonists, narcotic agonist-antagonists and drugs which are known to affect dopaminergic systems.
Because of known similarities of characteristics between
cyclazocine and narcotic agonists, another group of rats was
trained to discriminate between morphine and saline to provide critical comparisons.

3

In order to establish that the neuropharmacological basis of cyclazocine induced discriminative stimuli was different than the analgesic action of cyclazocine, cyclazocine
induced analgesia was tested in the presence of selected
neuroleptic drugs.

4

II.

A.

LITERATURE SURVEY

Multiple Forms of Opiate Receptors
Early investigations conducted in the chronic spinal

dog dealt with blockade of morphine's action with the partial agonist-antagonist, nalorphine and revealed a biphasic
reversal of morphine activity with increasing doses of nalorphine.

This lead to speculation that nalorphine was binding

to a separate opiate receptor in the central nervous system
(Martin, 1967).

Elaboration of these experiments lead to

the hypothesis that there were three stereochemically related
opiate receptors, which were designated mu (morphine), kappa
(ethylketocyclazocine) and sigma (SKF 10,047).

Each of these

receptor types was proposed to have separate spectrums of
activity when bound by agonists for that particular receptor.
Occupation of the mu receptor is characterized by miosis,
bradycardia, hypothermia, depression of nociceptive responses and indifference to environmental stimuli.

Kappa ago-

nists constrict pupils, depress the flexor reflex, and produce sedation but differs from mu agonists in not altering
skin twitch or pulse rate.

Sigma activity is characterized

by mydriasis, tachycardia, tachypnea and mania.
Based on the physiologic responses observed in the
chronic spinal dog following stimulation of each of these
receptors, Martin hypothesized the relative role of each
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receptor in the actions of many narcotic agents
al., 1976).

(Martin et

Morphine has been described as having high af-

finity and activity at the mu and kappa receptors while having no affinity at the sigma receptor.

Cyclazocine, nalor-

phine, pentazocine, oxilorphan and diprenorphine possess
high affinity but no activity at the mu receptor while having moderate to high levels of affinity and activity at the
kappa and sigma receptors.

Similar results have been re-

ported elsewhere (Pickworth and Sharpe, 1979).
In studies conducted in the rat, the similarity in
binding and distribution of mu and kappa receptors as well
as the prevention of new inactivation of these receptors by
3

H-naltrexone and

3

H-ethylketocyclazocine has lead to the

proposal that the kappa receptor may not exist in the rat
central nervous system (Hiller and Simon, 1979).

This re-

port does not dispute the existence of the three receptor
types in the dog as proposed by Martin.
In morphine dependent chronic spinal dogs, the administration 0£ the pure antagonists naloxone and naltrexone
precipitated a withdrawal syndrome with the most prominent
signs being hyperthermia, tachypnea, tachycardia, mydriasis
and continuous stepping, in that order (Martin et

~l.,

1974).

In chronic spinal dogs made dependent on cyclazocine, similar challenge with the pure antagonists produced a syndrome
with the most prominent signs being emesis, tachycardia and
hyperthermia (Gilbert and Martin, 1976).

In these and other
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experiments, it was found that 20 times as much naltrexone is
required to precipitate cyclazocine withdrawal as is required
to precipitate morphine withdrawal (Gilbert and Martin, 1976;
Pickworth and Sharpe, 1979).
The abstinence syndrome which emerges four to six hours
following cessation of morphine administration in the morphine dependent chronic spinal dog is suppressed by morphine
and d-propoxyphene. Cyclazocine, ethylketocyclazone and ketocyclazocine failed to suppress the morphine abstinence withdrawal syndrome (Martin et al., 1976).

In contrast to these

results, suppression of the abstinence withdrawal in the cyclazocine dependent chronic spinal dog was observed following the administration of cyclazocine, ethylketocyclazocine,
ketocyclazocine, pentazocine, morphine and nalorphine (Gilbert
and Martin, 1976).
Following chronic administration of N-allylnormetrazocine, a pure sigma agonist, the administration of naltrexone
or the abrupt withdrawal of drug produced syndromes characterized by enhanced flexor reflex, increased pulse rate and
decreased rectal temperature.

Signs which are commonly ob-

served in the withdrawn rrorphine dependent or cyclazocine
dependent chronic spinal dog were not observed in the N-allylnormetrazoc ine dependent dog (Martin et al., 1979).
In addition to the three receptors proposed by Martin,
a fourth type of receptor, the delta receptor, has been
proposed based upon the different potencies of naloxone in
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reversing binding of labeled alkaloids and peptides in the
guinea pig ileum and mouse vas deferens

(Hutchinson et al.,

1975; Lord et al., 1976) and guinea pig brain (Lord et al.,
1977).

Results from these experiments indicate that mor-

phine and morphine-like agonists are more potent in the guinea pig ileum, that naloxone readily reverses their effects
in the guinea pig ileum and mouse vas deferens and that
these types of agents more readily displace

3

H-naloxone,

3H-naltrexone or 3H-dihydromorphine than 3 H-enkephalin
(Beaumont and Hughes, 1979).

The receptors involved have

been characterized as beinq similar to the mu receptor proposed by Martin (Martin et al., 1976).

Conversely, enke-

phalin and enkephalin analogues have been described as delta
agonists in that their effects are more pronounced in the
mouse vas deferens, are not readily reversed by naloxone
and are more efficient in displacing 3 H-enkephalins as opposed to
1979).

3

H-naloxone or

3

H-naltrexone (Beaurnont and Hughes,

Beta-endorphin has been found to be equipotent as

an inhibitor of

3

H-enkephalin and 3 H-naloxone in the guinea

pig ileum and mouse vas deferens assays (Lord et al., 1977).
While it is generally agreed that the mu and delta receptors exist and that these two receptors show specificity
for alkaloids and enkephalins, respectively (Lord et al.,
1977; Chang and Cuatracasas, 1979), it has been proposed
that the differential binding of alkaloid agonist and antagonists may be due to changes in the conformation of a single
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receptor type (Smith and Loh, 1980).

Such a proposal stems

from the demonstration that sodium, added to incubation medium in binding assays, causes a potentiation of narcotic
antagonist binding (Pert and Snyder, 1974) while also causing an inhibition of agonist binding

(Simon~t~l.,

1973).

Treatment of tissues by the sulfhydryl blocker N-ethylmaleimide (NEM) caused a destruction of the opiate receptor
(Simon et al., 1973; Terenius, 1973).

This effect followed

first order kinetics which suggets that one receptor was
prevented by agonists, antagonists or pretreatment with sodium (Simon and Groth, 1975) .

B.

Clinical Use of Cyclazocine
Cyclazocine is a narcotic agonist-antagonist of

the benzomorphan series, the clinical use of which is based
upon its blockade of opiate receptors in the mammalian central nervous system.

Cychlazocine has therefore been em-

ployed in maintenance programs for patients physically dependent on narcotics (Chappel et al., 1974; Freedman et al.,
1968; Kleber et al., 1974; Martin et al., 1966; Resnick
et al., 1974).

Cyclazocine itself is considered to be of

low abuse potential (Martin et al., 1965).
Acute administration of cyclazocine to naive human subjects produces analgesia, miosis, respiratory depression
and constipation (Laskowitz et al., 1972), as well as dysphoric sensations described as tiredness, moodiness, misery,
anxiety, hallucinations and drunkenness (Martin et al., 1966;
Haertzen, 1970).
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Analgesia following 2 mg of cyclazocine is described as
being equally if not more potent than 10 mg of morphine.
Following repeated administration of cyclazocine, tolerance
develops to the analgesic and subjective effects but tolerance to the narcotic antagonistic properties of cyclazocine
is not observed (Martin et al., 1966).

--

Chronic administration of cyclazocine results in physical dependence as evidenced by the observation of an abstinence syndrome following abrupt withdrawal of the drug
(Martin

et~!·'

1965).

The signs of cyclazocine withdrawal

include rhinorrhea, lacrimation, hyperthermia and mydriasis.
While similar signs are observed during morphine withdrawal,
cyclazocine withdrawal syndrome is considered to be qualitatively different from the morphine withdrawal syndrome in
that the latter includes dramatic increases in blood pressure and respiratory rate while cyclazocine withdrawal showed
no change in either of these parameters.

In addition, cy-

clazocine withdrawal was not associated with drug seeking
behavior.
The cyclazocine abstinence syndrome is not detectable
until four or five days following cessation of drug and
does not become maximal until the seventh day.

Some signs

of withdrawal persist for as long as six weeks (Martin et
al., 1965).
Cyclazocine, administered to subjects physically dependent upon morphine or heroin, precipitates a withdrawal
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syndrome (Martin, 1965).

If, however, the subject is a post

addict, whose system is "clean" of narcotic agonists, cyclazocine administration will not produce a withdrawal syndrome
nor will it produce euphoria or any effects similar to morphine or heroin, but will prevent the subsequent administration of these agonists from having any agonistic effects upon the subject.

This effect of cyclazocine is reported to

last for 24 hours following a dose of 4 mg. of cyclazocine
as demonstrated by challenge with 15 mg of heroin I.V.
(Martin et al., 1966).

A similar effect is observed for 72

hours following a cyclazocine dose of 20 mg.
The pure narcotic antagonist, naloxone, is equipotent
with cyclazocine in reversing the effects of morphine.

Na-

loxone also antagonizes the pupillary, respiratory depressant, behavioral and subjective effects of cyclazocine
(Jasinski et al., 1968).

Such results would indicate that

the agonistic and antagonistic activities of cyclazocine
are mediated at different receptors.
The dysphoric effects produced by cyclazocine prevented
its use during early clinical trials (Freedman et al., 1968).
It was found that these effects could be minimized if a
treatment induction period of 21 days was employed during
which the dose of cyclazocine was increased in a gradual
manner.

When naloxone (5 mg/kg) was administered in conjunc-

tion with cyclazocine, so as to minimize the subjective effects, this induction period could be reduced to four days
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(Resnick,

1976).

~~al.,

All cyclazocine treatment of post

addicts was begun 14 days following the last dose of agonist so as to avoid precipitation of withdrawal.
When cyclazocine was first employed in clinical trials,
few subjects remained abstinant from opiates for any extended
period of time.

When cyclazocine therapy was conducted si-

multaneously with psychotherapy and counseling, 30% to 60%
of the patients were opiate free 6 to 27 months following
initiation of treatment (Resnick et al., 1976; Kleber
1974).

.~!. ~~.,

After 20 months of treatment, 8.5% of those patients

only receiving psychotherapy and counseling were opiate free
(Resnick et al., 1980).
--

Current research in antagonist therapy for opiate addiction is directed toward the development of antagonists which
are longer acting than cyclazocine.

One aspect of cyclazo-

cine activity which has unexpectedly been considered beneficial in clinical usage, and is being sought in long acting antagonists, is the unpleasant sensations experienced
upon stopping drug administration.

This quality is consid-

ered desirable in treatment of opiate addiction because it
has been found that patients maintained on cyclazocine were
less inclined to stop their medication without consulting
medical personnel first in light of the unpleasant syndrome
that would emerge.

Such encounters between staff and pa-

tient has proven to be of importance in maintaining patients
on such therapy (Resnick et al., 1980).
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C.

Cyclazocine Analgesia
Cyclazocine, when administered to human subjects

suffering from post operative or post partum pain and when
administered at doses as low as 0.25 mg., produced analgesia
which was described as equipotent or more potent than 10 mg
of morphine (Lasagna et al., 1964; Laskowitz, 1972).

The

consistent reports from subjects of the production of severe psychotomimetic effects however, have limited the clinical use of cyclazocine (Lasagna, 1964; Martin et al., 1965;
Haertzen, 1970).
Demonstration of cyclazocine analgesia in laboratory
animals initially proved to be a difficult task.

The mouse

tail flick procedure is a reliable method for demonstrating
narcotic analgesia (Dewey et al., 1969), but it proved to be
ineffective in demonstrating cyclazocine analgesia until it
was shown that the analgesic effects of cyclazocine in laboratory animals reach maximum levels one to five minutes
following drug administration (Dewey and Harris, 1971).
Physostigmine, itself being active in the mouse tail
flick procedure, enhanced the analgesic properties of cyclazocine (Harris et al., 1969).
Increase in adrenergic tone increased the toxicity of
cyclazocine and other agonist-antagonists but failed to alter the analgesic potency of cyclazocine in the mouse tail
flick procedure (Dewey et al., 1970).
Using the mouse tail immersion technique, Sewell and
Spencer (1975) demonstrated that intracerebroventricular
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administration of 5-hydroxy tryptamine (10 mg) potentiated
cyclazocine analgesia while similarly administered noradrenaline (10 mg) attenuated cyclazocine analgesia.
Intradermal administration of' ethylenediaminetetraacetic acid (EDTA) in the guinea pig produces a dose dependent
nociceptive stimulus (Teiger, 1976).

Cyclazocine, cyclor-

phan, nalorphine and pentazocine all produced a dose dependent decrease in the nociceptive response (Teiger, 1976). The
slopes of the dose response curves for the narcotic agonistantagoni sts were relatively parallel to the dose response
curves for other agonist-antagonists but were not parallel
to the dose response curves for morphine and other narcotic
agonists in the same analgesic assay.

This latter finding

agrees with previous findings that the narcotic agonistantagonists have a different analgesic profile in laboratory
animals than do morphine and other agonists (Harris and
Pierson, 1964; Dewey et al., 1970).

D.

Cyclazocine Effects Upon Animal Behavior
As has been demonstrated in the case of morphine

(Olds and Travis, 1960), the narcotic agonist-antagonists
cyclazocine and pentazocine have been shown to produce a
dose dependent decrease in lateral hypothalamic self-stimulation in the rat (Holtzman, 1976).

This effect was dose

dependently reversed by the narcotic antagonist, naloxone.
Naloxone at a dose of 1.0 mg/kg produced a 30-fold shift
to the right of the morphine dose response curve.

In the
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case of cyclazocine and pentazocine, however, 10 mg/kg nalox/

one produced only a ten-fold shift to the right of the cyclazocine and pentazocine curves.
Cyclazocine and pentazocine also produce dose-related
increases in continuous avoidance behavior and locomotor activity in the rat (Holtzman and Jewett, 1972).

These effects

were observed over a dose · range of 0.125 to 2 mg/kg.

Larger

doses of cyclazocine (4 to 8 mg/kg) were found to disrupt responding and decrease locomotor activity.

Naloxone reverses

the increase in avoidance behavior produced by cyclazocine
but is inactive in antagonism of the stimulation of locomotor activity (Holtzman and Jewett, 1973).
Stimulation of locomotor activity by the narcotic agonist-antagonist pentazocine was reversed by alpha methyl
paratyrosine, indicating that pentazocine stimulation may be
mediated by catecholamine release (Holtzman and Jewett,
1972).

Similar experiments have not been conducted with cy-

clazocine.
The stimulatory effect of cyclazocine upon discriminated
avoidance responding is preceded by an initial period of response inhibition (Wray, 1972).

These effects upon avoid-

ance responding were shown to be strikingly similar to the
effects o f LSD upon similar type behavior leading to speculation by the author that these agents may be acting through
similar central mechanism.
In an investigation of drug effects upon behavior controlled by interresponse time (DRL), d,l cyclazocine at doses
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of 3 and 5.6 mg/kg produced substantial increases in response
rate with concomitant decreases in number of reinforcements
received.

A dose of 10 ng/kg d,l cyclazocine disrupted re-

sponding as compared to cyclazocine vehicle sessions (AdamCarriere et al., 1978).
Cyclazocine produces increases in response rate in pigeons trained on an FR30 Fl5 schedule of reinforcement (McMillan and Harris, 1972).

High doses of cyclazocine caused

a decrease in resp:>nserates.

L-cyclazocine was found to be

30 times more potent in this effect than d-cyclazocine.
A syndrome of animal behavior consisting of lateral
head movements, pivoting on the hind paws and walking backwards has been shown to emerge in a dose dependent fashion
in the rat following administration of cyclazocine, levallorphan, pentazocine, nalorphine, phencyclidine, atropine,
mescaline and psilocybin but not following morphine, profodol
or saline (Schneider, 1968).

It is believed that observation

of this syndrome is predictive of the psychotomimetic effects produced by these drugs.

This bizarre behavior pro-

duced by cyclazocine and levallorphan is antagonized by apomorphine, piribedel, amphetamine, benztropine and 1-dopa
(Buckett and Shaw, 1975), indicating that dopaminergic systems are involved in the production of these behaviors and
suggesting dopaminergic involvement in the psychotomimetic
effects produced by these drugs.
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E.

Discriminative Stimulus Properties of Cyclazocine
The narcotic agonist-antagonist cyclazocine produces

a discriminative stimulus which controls operant responding
in the rat (Hirschhorn, 1977; Rosecrans et al., 1978; Teal
and Holtzman, 1980) and the squirrel monkey (Schaeffer and
Holtzman, 1978).

The discriminative stimulus properties of

cyclazocine are attenuated by the pure narcotic antagonist
naloxone (Hirschhorn, 1977; Rosecrans et al., 1978; Schaeffer
and Holtzman, 1978) but the dose of naloxone requir~d to
block the discriminative stimulus produced by cyclazocine is
from four to eighty times greater than the dose of naloxone
required to block the discriminative stimulus produced by
morphine (Gianutsos and Lal, 1975; Hirschhorn, 1977; Rosecrans et al., 1978; Schaeffer and Holtzman, 1978).
The discriminative stimulus produced by cyclazocine
generalizes to the narcotic agonist-antagonists butorphanol,
oxilorphan, levallorphan (Schaeffer and

l~ltzman,

1978), the

sigma agonist SKF 10,047 (Teal and Holtzman, 1979), ketocyclazocine (Schaeffer and Holtzman, 1978; Teal and Holtzman,
1979) and nalorphine (Rosecrans et al., 1978).

Naloxone re-

versed cyclazocine generalization to butorphanol and ketocyclazocine but was not effective in antagonizing generalization to oxilorphan or levallorphan (Schaeffer and Holtzman,
1978).

Cyclazocine did not generalize to morphine, pentazo-

cine, naloxone, nalbuphine or nalmexone (Hirschhorn, 1977;
Schaeffer and Holtzman, 1978; Teal and Holtzman, 1979).
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Cyclazocine produced drug appropriate responding in rats
trained to discriminate fentanyl from saline (Colpaert et
al., 1976) or morphine from saline (Hirschhorn and Rosecrans,
1976; Shannon and Holtzman, 1976, 1977), although these generalizations were not complete.
Based on reports that the subjectively experienced effects produced by cyclazocine in humans are psychotomimetic
in nature (Martin et al., 1965; Haertzen, 1970), several investigations have explored the possibility that the discriminative stimulus produced by cyclazocine in laboratory animals may be based upon similar central mechanisms.

Results

indicate that cyclazocine did not generalize to the nonopioid psychoactive drugs scopolamine, a-amphetamine, mescaline, pentobarbital or LSD (Schaefer and Holtzman, 1978;
Hirschhorn, 1977), but did generalize to ketamine and phencyclidine (Teal and Holtzman, 1979).

This latter effect was

not antagonized by naloxone.
In rats trained to discriminate LSD from saline, cyclazocine was found to substitute for LSD, although the generalization was only partial (Hirschhorn and Rosecrans, 1976).
Pentazocine, a narcotic agonist-antagonist which produces central effects similar to cyclazocine (Martins et al.,
1976), produces a discriminative stimulus in the rat (Kuhn
et al., 1976).

The discriminative stimulus strength of pen-

tazocine is subject to attenuation by the neuroleptic, haloperidol (Appel et al., 1978).
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F.

Discriminative Stimulus Produced by Narcotic Drugs
The narcotic analgesics, of which morphine is the

prototype, are a group of centrally acting agents whose principal effects include reduction of pain sensitivity, respiratory depression and the production of a euphoric state in
human subjects (Jaffe and Martin, 1975).

Despite its effi-

cacy in reducing the perception of pain, the usefulness of
morphine and other narcotics has been reduced by the fact
that tolerance develops to many of its central effects and
that physical dependence and addictive behavior are observed
following repeated administration.
Several clinical studies have indicated that the self
administration of narcotics is related to the subjective effects produced by these drugs (Eddy et al., 1970; Fraser
et al., 1961.
Recently, the discriminative stimulus properties of narcotic drugs were shown to be closely related to their centrally induced subjective effects (for discussion see Lal
et al., 1977; Colpaert, 1977).

In an effort to determine

the nature of these subjective effects, much attention has
been recently directed toward mechanisms underlying the discriminative stimulus produced by narcotic drugs.
The discriminative stimulus strength of morphine
(Shannon and Holtzman, 1976; Miksic and Lal, 1977) and fentanyl (Colpaert et al., 1975) have been shown to be dose related in nature in the rat.

Similarly, the morphine discrim-

inative stimulus also generalizes to other narcotic drugs in
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a dose dependent manner (Shannon and Holtzman, 1977; Miksic
et al., 1978) but does not generalize to non-narcotic psy-

-

-

choactive drugs (Gianutsos and Lal, 1976; Miksic et al.,
The narcotic antagonist naloxone (Gianutsos and Lal,
1976) and naltrexone (Shannon and Holtzman, 1977) produce
antagonism of the discriminative stimulus properties of morphine, while not producing drug appropriate responding when
injected alone.
The discriminative stimulus of morphine has been shown
to be based upon central rather than peripheral mechanisms
of this drug.

The principal peripheral effect of morphine

is decreased intestinal motility, thus leading to an antidiarrheal use of morphine (Jaffe and Martin, 1975).

Loper-

amide, a potent antidiarrheal agent (Stokkrehx et al., 1973)
which is devoid of analgesic and other mrophine-like central
effects (niemegeers et al., 1974), failed to produce drug
appropriate responding when administered to animals trained
to discriminate morphine from saline (Gianutsos and Lal,
1975).
It has also been demonstrated that the discriminative
stimulus properties of morphine are not based upon the analgesic effects of morphine.

Animals trained to discriminate

morphine and then subjected to increasing doses of morphine,
are still able to clearly discriminate the narcotic effect
although they have become tolerant to the analgesic properties of morphine (Miksic and Lal, 1977).
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The discriminative stimulus produced by fentanyl was antagonized by pretreatment with the neuroleptic pimozide,
while alpha methy l paratyrosine, azaperone, chlorpromazine
or pipamperone were not effective in blocking fentanyl discrimination

(Colpaert~!

al., 1977).

The nature of generalization of the morphine discriminative stimulus to the narcotic agonist-antagonists has .recently been shown to be determined by the training dose of morphine (Shannon and Holtzman, 1979).

A low training dose

(l . 25 mg/kg) of morphine generalized completely to the narcotic antagonist nalbuphine and d-amphetamine and partially
generalized to cyclazocine while a higher training dose (5.6
mg/kg) only partially generalized to nalbuphihe and did not
generalize to a-amphetamine or cyclazocine.
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III.

A.

METHODS AND lffiTERIALS

Animals
Fourteen male hooded rats of the Long-Evans strain,

random bred at the Charles River Breeding Laboratories,
Wilmington, Massachusetts and weighing between 300 and 350
grams were used in the discrimination experiments.

Animals

were singly housed in a room thermostatically controlled at
21 + 1°C with house lights turned off between 8 P.M. and 8
A.M.

Water was continuously available but food was limited

to approximately 20 grams per day made available 2 to 4 hours
following each daily session.

Animals' weights were main-

tained at approximately 300 grams using this feeding schedule.

B.

Drugs
Aceperone, benperidol, halopomide, haloperidol, oxi-

peromide and pipam perone were obtained through Janssen Pharmaceutica, Beerce, Belgium.

Cyclazocine, ethylketocyclazo-

cine and pentazocine were made available through the courtesy
of Sterling Wintrhop Research Laboratories, Rennsalear, New
York.

Dextro-amphetamine sulfate and chlorpromazine was ob-

tained from Smith, Kline and French Inc., Philadelphia,
Pennsylvania.

Endo Laboratories of Garden City, New York

generously provided naloxone hydrochloride.

D-butaclamol,
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1-butaclamol and dexclamol were supplied by Ayerst Laboratories of Montreal, Canada .

Nalorphine hydrochloride and ami-

triptyline were obtained from the Merck Co. Inc.

The Upjohn

Co. of Kalamazoo, Michigan generously provided the clozapine,
U 49,274A (Phenol, m-(8-(butylmethylamino)-l,4-dioxaspiro(4.5)dec-8-yl)-hydrochloride) and U-50,488E (Acetamide,2,-(3,4dichlorophenyl)-N-methyl-N-(2-(l-pyrrolidinyl)cyclohexyl)-,
trans-, monohydrochloride, hemihydrate).

C.

Equipment
Experiments were conducted in standard sound atten-

uated lever boxes obtained from Lehigh Valley Electronics,
Fogelsville, Pennsylvania .

Chambers were equipped with two

levers attached to one wall, placed equidistant on either
side of the food cup.
Boxes were electronically programmed for responses on
only one of the levers to be reinforced while responses on
the opposite lever were not

reinf~rced.

Automatic counters

were used to record the number of reinforcements delivered,
the number of incorrect responses made before delivery of
the first reinforcement and the total number of incorrect
responses made during a training session.
Forty-five milligram food pellets obtained from the
P.J. Noyes Company of Lancaster, New Hampshire were used
for reinforcement.

D.

Trainin g Procedure
Discrimination trainin g sessions were conducted
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on a daily basis.

Animals trained for cyclazocine discrim-

ination were injected with either cyclazocine (1.25 mg/kg)
or saline (1 ml/kg) fifteen minutes prior to being placed in
the operant chambers.

Animals trained for morphine discrim-

ination were injected with either morphine (10 mg/kg) or
saline (1 ml/kg) 15 minutes prior to being placed in the
operant chamber.
long.

All training sessions were ten minutes

Injection of drug or saline were alternated according

to an irregular sequence of injections.
Initial training sessions were conducted on a fixed ratio of one response for a reinforcement with the reinforced
lever alternated randomly.
these initial trials.

No injections were given during

When response rates on the FRl were

stabilized, the fixed ratio was gradually increased over the
course of several training sessions until an FRlO was
reached.
gun.

At this point drug and saline injections were be-

Each animal was assigned one lever as the drug lever

and the alternate lever as the saline lever.

Half of the

animals were reinforced on the left lever following drug administration and the right lever following saline injection.
Lever assignments were opposite to this in the remainder of
the animals.

These lever assignments did not change for the

remainder of the experiment.
Training sessions consisted of placing the animals in
the lever boxes 15 minutes after drug or saline administration.

Once placed in the chambers, the animals were allowed

to respond.

Responseson the reinforced lever were recorded
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as number of reinforcements delivered.

The actual number of

responses made on the reinforced lever was 10 times the
ber of reinforcements.

num~

A separate recording was made of the

number of responses made on the non-reinforced lever before
the delivery of the first reinforcement.

When the first re-

inforcement had been delivered, this recorder was automatically deactivated.
Responses made on the non-reinforced lever throughout
the training sessions were recorded separately.

This in-

eluded responses made on the non-reinforced lever before and
after the delivery of the first reinforcement.
When animals made not more than four incorrect responses
before the first reinforcement on ten consecutive training
days, they were considered to meet the discrimination criterion and were used for generalization testing.

E.

Testing Procedure
Testing was conducted once per week per animal in

the animals which maintained proper discriminative responding.

On generalization test days, animals were injected

with the test drug, fifteen minutes after which they were
placed in the operant chambers and allowed to complete ten
responses on one of the levers.
lever were also recorded.

Responses on the opposite

When ten responses had been re-

corded on either of the levers, the animal was removed from
the operant chamber and returned to the home cage.

The test

was recorded as a drug selection or a saline selection based
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upon which lever ten responses were completed first.
Drugs being tested for blockade or potentiation of the
cyclazocine or morphine discriminative stimuli were injected
at a predetermined interval before injection of cyclazocine,
morphine or one of the agents to which the training drugs
generalized.

Fifteen minutes following this second injec-

tion, a test, as described above , was conducted.
Discrimination training was conducted between tests with
eaah animal receiving drug and saline at least twice between
tests.

All tests were conducted on a day following a saline

training session.

Training sessions were conducted at least

six days per week.

F.

Analgesia Testing
Male albino mice of the CD-1 strain obtained from

the Charles River Breeding Laboratories were employed in the
analgesia experiments.

Mice were used in this portion of

the experiment due to inconsistency of cyclazocine analgesia
when demonstrated in the rat.

The tail flick apparatus was

EMDIE model TF-6.
Animals were hand-held in order that their tails could
be placed on the notched block so as to occlude the aperture
from the photocell.

Turning on the 100 watt heat lamp caused

simultaneous activation of a timer.

The lamp was placed

13 cm. above the platform so that heat was directed upon the
animal's tail.

When the animal flicked its tail, the photo-

cell was exposed to the light and the timer was automatically stopped.

The intensity of the larr.p was adjusted so that
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control latencies ranged from two to four seconds.
were recorded to 0.1 sec.

Latencies

Animals with latencies outside of

this range were always discarded from the experiment.
In measuring cyclazocine analgesia, control latencies
were recorded for each animal.

Cyclazocine was then adminis-

tered at the predetermined doses.

Tail flick latency was

recorded five minutes and 35 minutes following cyclazocine
administration.

When investigating possible drug induced al-

teration of cyclazocine analgesia, the drug being employed
in combination with cyclazocine was administered after control latencies were recorded.

With several animals from each

group, a second recording was done before cyclazocine administration to insure that pretreatment agents did not have
analgesic properties themselves.
Oxiperomide, haloperidol, pipamperone, halopomide
(R-34-301), 1-butaclamol and aceperone were administered 60
minutes prior to cyclazocine.

Clozapine and dexclamol were

injected 30 minutes before cyclazocine while naloxone was
injected 10 minutes before cyclazocine.
Analgesic latencies were defined as those which exceeded
the group control mean by more than three standard deviations.

All data is recorded as percent animals tested with

analgesic latencies.
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IV.

A.

RESULTS

Training
Animals trained to discriminate cyclazocine (1.25

mg/kg) from saline met testing criteria in 41.50
training sessions (n=l4)

(Table 1) .

~

1.66

Several animals were

sedated by the training dose of cyclazocine and were unable
to respond during several of the initial drug training sessions.

Tolerance to this effect was observed in all cases

within three training sessions .
. In agreement with previous results (Miksic, Shearman
and Lal, 1978; Miksic and Lal, 1977; Gianutsos and Lal, 1975),
the morphine saline trained animals met testing criteria in
fewer than 40 training sessions.

B.

Generalization-Cyclazocine Discriminative Stimulus
In animals trained to discriminate cyclazocine from

saline, 100 % of animals tested responded on the drug lever
following administration of the cyclazocine training dose of
1.25 mg/kg.

The average response rate during cyclazocine

training sessions was 85.3 + 7.4 responses per minute (n=l4)
(Table 2).

Following saline injection (1 ml/kg), 100% of

the animals tested responded on the saline lever.

The re-

sponse rate during saline training sessions was 93.6 + 7.3
responses per minute (n=l4)

(Table 2) .
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TABLE 1.

NUMBER OF TRIALS REQUIRED TO MEET TESTING CRITERIONl
IN ANIMALS TRAINED TO DISCRIMINATE CYCLAZociNE
(1.25 mg/kg)

Animal No.
1
2
3
4
5
6
7
8

9
10
11
12
13
14
Mean + S.E.

2

FROM SALINE.

# Trials
45
50
42
41
39
52
46
41
47
30
35
36
42
35
41.5 + 1.6

1.

Testing criterion was to not emit more than four responses on the incorrect lever before the first reinforcement on ten consecutive trials.

2.

Administered 15 minutes before training session.
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TABLE 2.

RE SPONSE RATES FOR ANI MALS TRAINED TO DISCRIMINATE
CYCLAZOCINE FROM SALINE

l
Res ponses per 10 Minute Session (Mean + S . E . )
Animal No.

Cyclazocine

2

Saline

l

443 + 41

556 -+ 45

2

1401 + 33
-

1309 + 51
-

3

735 + 38
-

873 + 39
-

4

850 + 52
-

924 + 75
-

5

774 + 39

933 + 44

6

684 -+ 26
-

718 + 40
-

7

1047 + 54

1059 -+ 47

8

740 -+ 90

1453 + 53
-

9

6 34 + 59
-

977 + 62
-

10

1341 + 56
-

1297 + 29

11

731 + 65
-

890 + 90
-

12

817 + 29
-

897 + 49
-

13

614 + 38
-

, 590 + 40
-

14

1129 + 67
-

625 + 53
-

853 + 74

936 + 73
-

Mean + S.E.
1.

Based on 10 consecutive determinations commencing on
day 150 of the experiment.

2.

1.25 mg/kg, administered 15 min. before measurement.
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Injection of the cyclazocine vehicle, 0.3% tartaric acid
resulted in 100 % saline lever selection with response rate
being similar to those observed following saline.
When the dose of cyclazocine was decreased on a log dose
basis, a dose related decrease in percent animals selecting
the drug lever was recorded (r=0.91)

(Table 3).

Following administration of the partial agonist antagonist ethylketocyclazocine, rats trained to discriminate cyclazocine from saline selected the drug lever in a dose
dependent fashion (r=0.91)

(Table 3).

One hundred percent

of the animals tested selected the drug lever following
ethylketocyclazocine 0.32 mg/kg.
The narcotic agonist-antagonist pentazocine produced
dose related increases in percent animals selecting the drug
lever with 100 % selecting the drug lever following a dose of
20 m/gkg.

Increasing the pentazocine dose to 40 mg/kg re-

sulted in a decrease in the ratio of animals selecting the
drug lever with 70% selecting the drug lever following this
dose (Table 3).
U-49,274A and U-50,488E, experimental narcotic agonistantagonists produced by the Upjohn Company, each produced
drug lever selection.

The highest dose of U-49,274A tested

(40 mg/kg) resulted in 40 % drug lever selection with 60 % of
the animals tested unable to respond.

No higher doses were

tested.
The highest percent animals selecting the drug lever
following U-50,488E was 50 % following 10 mg/kg with percent

GENERALIZATION OF THE DISCRIMINATIVE STIMULUS
PRODUCED BY CYCLAZOCINE (1. 25 mg/kg) TO
NARCOTIC DRUGSl

TABLE 3.

Responses on Unselected Lever
Before First Reinforcement
(Mean + S . E . )
% Selecting
Cyclazocine Lever

Following
Drug Selection

Following
Saline Selection

Drug

Dose

N

CYCLAZOCINE

0.005

9

0

16

25

0.08

11

27

0 . 32

8

32

1. 67+0 . 88 ( 5)

0.64

15

87*

0 . 23+0 . 23 (13)

1. 25

14

100*

0

No saline selection

2 . 50

7

100*

0

No saline selection

0 . 08

6

17

0

2 .40+1 . 36 ( 5)

0.16

4

25

0

0

0 . 32

4

100*

0.64

4

25

2.50

7

43

2.67+2 . 19 ( 3)

1 0 . 00

8

100*

1.13+0. 74 (8)

0 . 02

ETHYLKETOCYCLAZOCINE

NALORPHINE

No drug selection
0.38+0 . 38 (16)

-

1.58+0.80 ( 12)

-

0

0

-

2 . 50+1. 66 (4)
0

1.60+1.60 ( 5)
0

-

No saline selection
2 . 33+2 . 33 ( 3)

-

1.50+0 . 63 (4)
No saline solution

w
t-'

TABLE 3 (continued)

Responses on Unselected Lever
Before First REinforcement
(Me an + S . E . )
% Selecting
Cyclazocine Lever

Following
Drug Selection

Following
Saline Selection

Drug

Dose

N

PENTAZOCINE

2.50

7

14

1.00+0 (1)

10.00

5

80

20.00

5

100

3 . 25+1.18 (4)
1. 20+1. 20 ( 5)

40.00

10

70

1.43+0.69 ( 7)

2.33+1.86 ( 3)
-

20.00

8

25

3.00+2.45 ( 2)

3.17+1.62 ( 6)

40.00

5

60

2.50

5

20

10.00

8

50

20.00

4

25

2.50

6

17

5.00

8

50

1.75+0.85 (4)

10. 00

6

100

(6)

0.16

7

0

No drug selection

0

10.00

9

0

No drug selection

0.40+0.24 (5)

40.00

5

0

No drug selection

0

U-49, 274A

u-50, 488E

MORPHINE

NALOXONE

0

-

-

-

-

9.0+0 (1)

-

No saline selection

-

5.67+1.86 (3)

0

0.50+0.29 ( 4)

5.00+0 (1)

-

-

2 .00+1. 35 (4)

0
8.00+0 ( 1)

0

-

1.60+1.36 ( 5)

0

3.67+1.65
-

-

0
No saline selection

-

lAll drugs and doses administered 15minutes prior to testing.
*Statistically significant difference
saline lever selection (n=l4) .

(p~0.05)

by Fisher Exact Probability in comparison with 100 %

w
l\J

33
selecting the drug lever decreasing to 25% following a dose
of 20 mg/kg.
The discriminative stimulus produced by cyclazocine
completely generalized to the pure narcotic agonist morphine
(Table 3).

Dose related increases in percent selection of

drug lever were observed with 100% drug lever selection following a dose of 10 mg/kg (r=0.99).
The pure narcotic antagonist, naloxone, produced saline
lever selection in all animals tested and at all doses tested
from 0.64 mg/kg to 40.0 mg/kg.
In order to investigate the possible biogenic amine basis of the cyclazocine discriminative stimulus, selected
agents were tested for generalization to the cyclazocine discriminative stimulus.
The direct and indirect dopamine receptor stimulants
apomorphine and a-amphetamine were tested for generalization.
All doses of apomorphine tested produced saline lever selection (Table 4).

In the case of a-amphetamine, a dose of 0.64

mg/kg generalized to saline.

A dose of 1.25 mg/kg resulted

in two of the five animals tested selecting the drug lever.
Dopaminergic receptor blockers also produced saline
lever selection.

The agents used in these tests included

bemperidol (0.32 mg/kg), d-butaclamol (0.16 mg/kg), 1-butaclamol (0.16 mg/kg), clozapine (5.0 mg/kg), dexclamol (0.16
(mg/kg), haloperidol (0.32 mg/kg) and oxiperomide (0.16 mg/kg)
(Table 4).
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TABLE 4.

GENERALIZATION OF THE DISCRIMINATIVE STIMULUS PRODUCED BY
CYCLAZOCINE (l.25 mg/kg) TO NON-NARCOTIC PSYCHOACTIVE DRUGS

Responses on Incorrect Lever
(Mean + S .E.)
N

Drug
Lever

0.64

4

0

2. 50+1. 50 (2)

1.25

l

0

0

0.16

3

0

0

0.64

7

0

0

1.25

5

40

HALOPERIOOL

0 .. 32

4

0

0

d-BUTACLAMOL

0.16

5

0

0

1-BUTACLAMOL

0.16

6

0

0

BENPERIOOL

0. 32

5

0

0

CLO ZAP I NE

5.00

9

0

0

OXIPEROMIDE

0.16

7

0

0

DEXCLAMOL

0.16

5

0

0

HALOPOMIDE

2.50

2

0

0

10 .00

6

0

0

0.16

4

0

0

DESIPRAMINE

10.00

9

0

0

AMITRIPTYLINE

30.00

3

0

0

ACEPERONE

2 .5 0

5

20

BUTORPHANOL

0.16

4

0

Drug
APOMORPHINE

d-AMPHETAMINE

CLONIDINE

Dose (mg/kg)

-- - - -

Q_rug Selection Saline Selection

0.50+0.50 ( 2)

0

(2)

1.0+0

0
0. 75+0. 75 (4)
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Halopomide (R34-301), a compound which reportedly blocks
peripheral dopaminergic receptors, ·when tested for generalization at doses of 2.50 and 10.0 mg/kg resulted in 100% saline lever selection.
Clonidine (0.16 mg/kg), an alpha

1

adrenergic agonist, pro-

duced saline lever selection (Table 4).
The tricyclic antidepressants amitriptyline and desipramine both produced saline lever selection in all animals
tested (Table 4).
Aceperone, an alpha adrenergic blocker, administered at
a dose of 2.50 mg/kg produced 20% drug lever selection (n=5)
(Table 4).

Butorphanol reportedly having narcotic agonist-

antagonist properties produced 100% saline lever selection
(Table 4).

C.

Naloxone Blockade of Cyclazocine Discriminative Stimulus
In agreement with previous reports (Hirschhorn, 1977;

Rosecrans et al., 1978; Schaeffer and Holtzman, 1978; Teal
and Holtzman, 1980), naloxone produced a dose dependent blockade of the cyclazocine discriminative stimulus (Table 5).
Naloxone administered in doses of 2.5 or 10.00 mg/kg fifteen
minutes prior to the cyclazocine training dose resulted in
diminished percent drug lever selection.

Complete blockade

of the cyclazocine discriminative stimulus was observed following naloxone 40 mg/kg i.e., 100 % of the animals tested selected the saline lever.
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TABLE 5.

ANTAGONISM OF DISCRIMINATIVE STIMULUS PRODUCED
BY CYCLAZOCINE (l. 2S mg/kg) BY NALOXONEl

Responses on Unselected Lever
Before First Reinforcement
(Mean + S . E . )
Naloxone
Dose (mg/kg)

N

% Selecting
Cyclazocine
Lever

Following Drug
Lever Selection

Following Saline
Lever Selection

0

14

100*

0

No saline selection

0.64

6

100*

0

No saline selection

2.50

5

60*

10.00

7

14

40.00

5

0

0 . 33+0.33 (3)
0

No drug selection

0

1. 67+0 .80 ( 6)
0

1.

Naloxone administered 15 minutes prior to cyclazocine (1. 25 mg/kg)

2.

Statistically significant difference (pL 0.05) by Fisher Exact
Probability in comparison with 100 % saline lever selection (n=l4).
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Naloxone also antagonized generalization of the cyclazocine discriminative stimulus to morphine (10 mg/kg)

(Table 6).

Complete blockade of this generalization was achieved following naloxone 1.25 mg/kg.
Generalization of the cyclazocine discriminative stimulus to nalorphine (10 mg/kg) was not completely blocked by
naloxone at any dose of naloxone tested (Table 7).

Although

naloxone at a dose of 0.64 mg/kg reduced percent drug lever
selection from 100% to 57%, further increases in the naloxone
dose, up to 40 mg/kg, resulted in approximately 25% drug lever selection.

D.

The Effects of Neuroleptics Upon the Cyclazocine Discrim-

inative Stimulus
In order to investigate a possible dopaminergic component in the cyclazocine discriminative stimulus, several
neuroleptics were employed as pretreatments to cyclazocine
before generalization testing.

Initial portions of this ser-

ies of experiments were conducted at the training dose of
cyclazocine, 1.25 mg/kg.

The dosages of neuroleptics which

were used in these experiments were decided upon in light of
previous results in animal experimentation using these same
drugs.
The neuroleptic, d-butaclamol, when administered at a
dose of 0.16 mg/kg 60 minutes prior to cyclazocine, produced
a statistically significant attenuation of the cyclazocine
discriminative stimulus (Table 8.
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TABLE 6.

ANTAGONISM OF CYCLAZOCINE DISCRIMINATIVE STIMULUS
GENERALIZATION TO MORPHINE (10 mg/kg) BY NALOXONE

Responses on Unselected Lever
Before First Reinforcement
(Mean + S.E.)
Naloxone
Dose (mg/kg)

N

% Selecting
Cyclazocine
Lever

0

6

100*

0.08

5

80*

0.32

6

so

1.25

4

0

Following Drug
Lever Selection
0

4 . 25+1.93 (4)
0

Following Saline
Lever Selection
No saline selection
0
0

No drug selection No saline selection

1.

Naloxone administered 15 minutes prior to morphine (10 mg/kg).

*

Statistically significant difference (pL 0 . 05) by Fisher Exact
Probability in comparison with 100% saline lever selection (n=l4).
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TABLE 7.

ANTAGONISM OFCYCLAZOCINE DISCRIMINATING STIMULUS
GENERALIZATION TONALORPHINE (10 mg/kg) BY
NALOXONEl

Responses on Unselected Lever
Before First Reinforcement
(Mean + S.E.)
Naloxone
Dose (mg/kg)

N

% Selecting
Cyclazocine
Lever

0

4

100%

1.13+0. 74 ( 8)

0.64

7

57*

0.25+0.25 (4)

2.50

8

25

.3.50+3.50 (2)

10 .00

8

38

2. 00+1. 53 ( 3)

0

20.00

9

11

0

0

8

25

3.00+3.00 (2)

0

40.00

Following Drug
Lever Sele·ction

Following Saline
Lever Selection
No saline selection
0
1. 33+1. 33 (8)

1.

Naloxone administered 15 minutes prior to nalorphine.

*

Statistically significant difference (pL0.05) by Fisher Exact
Probability in comparison with 100% saline lever selection (n=l4).

TABLE 8.

THE EFFECTS OF NEUROLEPTIC PRETREATMENT UPON DISCRIMINATIVE STIMULUS PRODUCED BY CYCLAZOCINE

Responses on Unselected Lever
Befor e First Reinforcement
(Mean + S . E: )

Dose (mg/kg}

Drug

Dose
(mg/kg}

1. 25

N
14

% Selecting
Cyclazocine Lever

Following Drug
Lever Selection

100*

0

d-BUTACLAMOL

0 .16

6

33

0

1-BUTACLAMOL

0.16

6

100*

0

HALOPERIDOL

0. 32

7

57*

3.00+0 (1)

OXIPEROMIDE

0 .1 6

7

100*

7.00+0 ( 1)
-

OXIPEROMIDE

0.64

4

100*

0

Following Saline
Lever Selection
No saline selection
0
No saline selection
4.00+0 (1)
No saline selection
No saline selection

1.

Neuroleptics administered one hour prior to cyclazocine (.25 mg/kg).

*

Stati st ically significant difference (pL0. 05 ) by Fisher Exact Probability in comparison with
100 % saline lever selection(n=l4).

8
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L-butaclamol, an enantiomer devoid of neuroleptic activity, was ineffective in altering the . discriminative stimulus
strength of cyclazocine (Table 8) .
Haloperidol (0.32 mg/kg), a member of the butyrophenone
series of neuroleptics, produced a blockade of the cyclazocine discriminative stimulus which was not significantly different from saline pretreatment (Table 8).
Oxiperomide, a dopaminergic antagonist specifically active in the gut and at the chemoreceptor trigger zone, did
not produce a blockade of the cyclazocine discriminative
stimulus at either of the two doses tested (0.16 mg/kg) and
0. 64 mg/kg)

(Table 8) .

In view of the fact that the discriminative stimulus
strength of cyclazocine at a dose of 1.25 mg/kg might represent a plateau effect at the higher rang es afthe dose-response curve, and that the possible blocking properties of
neuroleptics tested might be masked by such an effect, additional experiments dealing with cyclazocine discriminative
stimulus blockade by neuroleptics were conducted with cyclazocine 0.64 mg/kg.
In subsequent experimentation, haloperidol (0.32 mg/kg)
produced a blockade of the cyclazocine discriminative stimulus which was statistically significant (Table 9).

In this

test, the percent animals selecting the drug lever was decreased from 87 % (n=l5) with no pretreatment to 18% (n=ll)
with haloperidol pretreatment.

TABLE 9.

THE EFFECTS OF NEUROLEPTIC PRETREATMENT
PRODUCED BY CYCLAZOCINE

1

UPON THE DISCRIMINATIVE STIMULUS

Responses on Unselected Lever
Befor e First Reimforcement
( Mean+ S.E.)
Cyclazocine
Dose (mg/kg)

Drug

Dose
(mg/kg)

0.64

%

N

-

15
BENPERIOOL
2
CLOZAPINE
2
CLOZAPINE

Selecting
Lever

~clazocine

Following Drug
Lever Selection

87*

3.00 + 0 ( 1)

-

Following Saline
Lever Selection
No saline selection

0.32

5

20

0

5.00

9

56*

0

10. 00

6

67*

0

DEXCLAMOL

0.16

5

60

4.00 + 0 (1)

HALOPERIOOL

0.08

9

100*

0

0

HALOPERIDOL

0.32

11

18

0

0

0
8.00 + 0 ( 3)

-

0
4.00 + 0 ( 1)

-

1.

Neuroleptics administered one hour prior to cyclazocine (0.64 mg/kg)

2.

Clozapine administered 30 minutes prior to cyclazocine.

*

Statistically significant difference (pL0.05) by Fisher Exact Probability in comparison with
100% saline lever selection (n=l4) .

.t>

;0
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A smaller dose of haloperidol was found to be ineffective in blocking the discriminative - stimulus properties of
cyclazocine.
A similar attenuation of the cyclazocine discriminative
stimulus was observed following pretreatment with benperidol
(0.32 mg/kg) 60 minutes prior to cyclazocine (0.64 mg/kg)
(Table 9).
Clozapine, a weak neuroleptic which produces few extrapyramidal side effects, was found to produce some blockade of
the cyclazocine discriminative stimulus, although this effect
of clozapine was not found to be statistically significant
(Table 9).
Similarly, dexclamol, a soluble form of the previously
mentioned butaclamol, was found to have stimulus blocking
effects which were not within a statistically significant
range (Table 9).

E.

The Effects of D-Amphetamine Upon the Cyclazocine Dis-

criminative Stimulus
D-amphetamine (0.64 mg/kg) pretreatment fifteen
minutes prior to cyclazocine administration caused no detectable change in the discriminative stimulus properties of cyclazocine (Table 10).

F.

Generalization - Morphine Discriminative Stimulus
Animals trained to discriminate morphine (10 mg/kg)

from saline (1 ml/kg) selected the drug lever 100% of the
trials following this training dose.

The percent animals

TABLE 10.

THE EFFECTS OF d-AMPHETAMINE PRETREATMENTl UPON THE
DISCRIMINATIVE STIMULUS PRODUCED BY CYCLAZOCINE

Responses on Unselected
Lever (Mean+ S.E.)
d-Ampetamine
Dose (mg/kg)

1.

Cyclazocine
Dose (mg/kg)

% Selecting

N

Drug Lever

0.64

0

7

0

0.64

0.02

7

14

0.64

0.08

7

57

0 . 64

0.32

7

71

Following Drug
Lever Selection

Following Saline
Lever Selection
0

1. 0 + 0 ( 1)
2.50 + 1.66 (4)
0

0

3.67 + 2.67 (3)
0

Administered 15 minutes prior to cyclazocine.

.s::.
~
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selecting the drug lever decreased with decreases in the dose
of morphine administered (r=0.89)

(Table 11).

The partial agonist-anta gonist, cyclazocine, produced
drug lever selection in animals trained to discriminate morphine from saline.

This generalization was not complete in

that at no dose tested did 100 % of the animals tested select
the drug lever (r=Q.90)

(Table 12).

Ethylketocyclazocine, also a partial agonist-antagonist,
produced drug lever selection in animals trained to discriminate morphine from saline (Table 12) .

Increases in percent

animals selecting drug lever was observed when the dose of
ethylketocyclazocine was increased fron 0.08 mg/kg to 0.32
mg/kg.

Further increases in dose to 0.64 mg/kg and 1.25

mg/kg produced a percent drug lever selection decrease.
The pure narcotic antagonist, naloxone, produced exclusive saline lever selection at all doses tested (Table 12).

G.

Naloxone Blockade of .Morphine Discriminative Stimulus
Naloxone produced a dose dependent blockade of the

morphine discriminative stimulus when administered 15 minutes prior to morphine injection (r=0.99)

(Table 13).

Com-

plete blockade was recorded following naloxone 0.32 mg/kg.
When nalo xone was administered 15 minutes prior to cyclazocine (1.25 mg/kg) in rats trained to discriminate morphine from saline, there was a diminished percent animals
selecting the drug lever as compared to saline injection or
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TABLE 11.

RESPONSE RATES FOR ANIMALS · TRAINED TO DISCRIMINATE
MORPHINE FROM SALINE

Responses per 10 Minute Session (Mean + S .E.)
2

Animal No.

Morphine

1

832 + 68

1240 -+ 59

2

557 + 50

981 -+ 85

3

600 -+ 64

989 -+ 50

4

748 + 45
-

1015 + 69

5

736 + 77

1218 + 46

6

181 + 35

795 + 72
-

7

682 -+ 91

1097 + 62
-

8

451 + 49

903 + 70
-

9

200 + 16
-

446 + 60

10

795 + 64
-

874 -+ 49

11

323 + 25

746 + 46
-

12

590 -+ 16

972 -+ 42

558 + 65

940 + 62

Means + S. E.
-

Saline

1.

Bas e d upon 10 consecutive determinations commencing on day 150 of
experiment.

2.

10 mg/ kg, given 15 minutes before measurement.

1

47

TABLE 12.

GENERALIZATION OF THE DISCRIMINATIVE STIMULUS PRODUCED BY
MORPHINE (10 mg/kg) TO NARCOTIC DRUGs.l

N

%
Selecting
Morphine
Lever

0. 64

5

20

1. 25

5

0

2.50

17

47*

5.00

7

57*

10.00

12

100*

0.08

7

43

1.6741.67 ( 3)

0.32

8

38

0.33+0.33 ( 3)

1. 25

8

88*

2.50

5

80*

0.08

5

0

0.16

10

10

0.32

7

71*

4.40+1.80 ( 5)

0

0.64

4

50

3.00+1.73 ( 3)

0

1.25

4

0

No drug selection

0

0.005

5

0

No drug selection

0

0.08

5

0

No drug selection

0.32

2

0

No drug selection

Dose
(mg/kg)

Drug

MORPHINE

CYCLAZOCINE

ETHYLKETOCYCLAZOCINE

NALOXONE

Responses on Unselected Lever
Before Firs t Reinforcement
(Mean + S . E . )
Following Drug
Lever Selection

0
No drug selection
0
1.50+1.19 (4)
0

0

Following Saline
Lever Selection

0
0
1.11+0. 75 (9)
No saline selection
No saline selection
1. 75+1. 03 ( 4)
0
0

0.25+0.25 ( 4)

0

No drug selection

0

0

0

0.40+0.40 ( 5)
0

1.

All drugs and doses administered 15 minutes prior to testing.

*

Statistica lly significant diff e rence (p LQ.05 ) by Fisher Exact Probability in comparison with 100% saline lever selection (n=l2) .
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TABLE 13.

ANTAGONISM OF DISCRIMINATIVE ' STIMULUS PRODUCED BY MORPHINE
(10 mg/kg) BY NALOXONEl

Responses on Unselected Lever
Before First Reinforcement
(Mean + S.E.

%

Naloxone
Dose (mg/kg)

N

Selecting
Morphine
Lever

2

Following Drug
Lever Selection

Following Saline
Lever Selection

0

12

100*

6.891*

0

No saline selection

0.08

4

100*

4.701*

0

No saline selection

0.16

5

60

2.761

1.67+1.20 ( 3)

0

0.32

6

0

No drug selection

0

1.

Naloxone administered 15 minutes prior to morphine (10 mg/kg).

*

Statistically significant diff e rence (pL.0.05) by Fisher Exact
Probability in comparison to 100% saline lever selection (n=l2) .
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no injection prior to cyclazocine (r= -0.98)

(Table 14).

Com-

plete blockade was observed following naloxone 1.25 mg/kg.
Nonnarcotic psychoactive drugs which resulted in saline
lever selection included d-butaclamol (0.16 mg/kg), 1-butaclamol (0.16 mg/kg), d-amphetamine (0.64 mg/kg), haloperidol
(0.32 mg/kg), chlorpromazine (10 mg/kg) and clonidine (0.16 ·
mg/kg)

H.

(Table 15).

The Effects of Neuroleptics Upon the Morphine Discrimina-

tive Stimulus
The butyrophenone neuroleptic, haloperidol, when administered at a dose of 0.32 mg/kg, 60 minutes prior to morphine injection, produced a statistically significant decrease
in the percent animals selecting drug lever follow1ng morphine
at doses of 2.5 and 10 mg/kg when compared to saline pretreatment before morphine at these doses (Table 16).
Attenuation of the morphine discriminative stimulus was
not observed following pretreatment with the neuroleptics
d-butaclamol (0.16 mg/kg), 1-butaclamol (0.16 mg/kg) and
clozapine (2.5 mg/kg).
Following pretreatment with chlorpromazine (10 mg/kg) and
declamol (0.16 mg/kg), animals were unable to respond due to
sedation.

I.

Cyclazocine Analgesia - Mouse Tail Flick
Cyclazocine was tested for analgesia at doses of 2.5

mg/kg and 5.0 mg/kg.

At the smaller dose of cyclazocine, 20%

.so

TABLE 14.

ANTAGONISM OF MORPHINE DISCRIMINATIVE STIMULUS GENERALIZATION
TO CYCLAZOCINE (1 . 25 mg/kg) BY NALOXONEl

%

Re sponses on Unselected Lever
Before First Reinforcement
(Mean + S.E . )

Naloxone
Dose (mg/kg)

N

Selecting
Morphine
Lever

0

8

88*

0

0.08

4

100*

0

0.32

6

33

0

0

1. 25

6

0

No drug selection

0

1.

Following Drug Following Saline
Lever Selection Lever Selection
0

No saline selection

Naloxone administered 15 minutes prior to cyclazocine (1.25 mg/kg)

*
Statistically signi f icant difference fp L 0 . 05) by Fisher Exact
Probability in comparison with 100% saline lever selection (n=l2).
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TABLE 15.

GENERALIZATION OF THE DISCRIMINATIVE STIMULUS PRODUCED BY
MORPHINE (10 mg/kg) TO NON-NARCOrIC PSYCHOACTIVE DRUGS

%

Selection
Morphine
Lever

Responses on Unselected Lever
Before First Rei nforcement
( Mean + S . E . )
Following Drug
Lever Selection

Following Saline
Lever Selection

Drug

Dose

N

d-BUTACLAMOL

0.16

4

0

No drug selection

0

1-BUTACLAMOL

0.16

6

0

No drug selection

0

d-AMPHETAMINE

0.64

4

0

No drug selection

0.75+0.75 (4)

HALOPERIOOL

0.32

8

0

No drug selection

0.63+0.50 ( 8)

CLONIDINE

0.16

4

25

0

3.00+3.00 ( 3)

52

TABLE 16.

l

THE EFFECTS OF HALOPERII:DL PRETREATMENT UPON THE DISCRIMINATE
STIMULUS PRODUCED BY MORPHINE (10 ~g/kg)

9o

Halo per idol
Dose (mg/kg)

Morphine
Dose
(m.g :/kg ) N

Selecting
Morphine
Lever

Responses on Unselected Lever
Before First Reinf orcement
(Mean + S.E.)
Following Drug
Lever Selection

Following Saline
Lever Selection

5.00 + 1.00 (2)

0

2.50

17

47*

0

0

10.00

12

100*

0

0.32

2.50

16

13

0

6.00 + 3.01 (2)

0.32

10.00

7

57

0

1.00 + 0 (1)

1.

Haloperidol administered one hour prior to morphine.

*

Statistically significant difference (p 2 _0.05) by Fisher Exact
Probability in comparison to saline pretreatment.
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of the animals tested were analgesic at five minutes post injection and 10% were analgesic at 35 minutes post injection
(n=lO).

A dose of 5.0 mg/kg cyclazocine produced analgesia

in 58% of animals tested five minutes following injection
and 32% of the animals tested 35 minutes following injection
(n=l9)

(Table 17).

The analgesic properties of cyclazocine were antagonized
by the narcotic antagonist, naloxone (10 mg/kg)

J.

(Table 17).

The Effects of Neuroleptic Pretreatment Upon Cyclazocine

Analgesia
Oxiperomide (0.64 mg/kg), administered one hour
prior to cyclazocine (2.5 mg/kg), produced a significant increase in the percent animals with analgesic latencies 35
minutes after cyclazocine injection as compared to groups of
animals receiving saline pretreatment (Table 18).

In saline

pretreated animals, cyclazocine (2.5 mg/kg) administration in
20% animals tested having analgesic latencies five minutes
after cyclazocine while 10% of the animals had analgesic
cies after 35 minutes (n=lO).

laten~

In animals receiving oxipero-

mide (0.64 mg/kg) pretreatment, 89% of the animals had analgesic latencies five minutes after cyclazocine while 100% of
these animals had analgesic latencies 35 minutes after injection (n=9).

Oxiperomide administered alone does not produce

analgesia.
Clozapine (2.5 mg/kg), administered 30 minutes prior to
cyclazocine (2.5 mg/kg), produced a potentiation of the
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TABLE 17.

1
THE EFFECTS OF NALOXONE UPON CYCLAZOCINE ANALGESIA USING
MOUSE TAIL FLICK PROCEDURE

%

Analgesia

2

Naloxone
nose (mg/kg)

Cyclazocine
Dose (mg/kg)

N

5 Minutes

35 Minutes

0

2.50

10

20

10

0

5.00

19

58

32

10

2.50

10

0

0

10

5.00

8

0

0

1.

Naloxone administered 10 minutes prior to cyclazocine.

2.

Analgesic latencies exceed group control mean by three standard
deviations or more.
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TABLE 18.

THE EFFECTS OF NEUROLEPTIC PRETREATMENT UPON CYCLAZONE
ANALGESIA

%

Drug

Dose (mg/kg)

SALINE
OXIPEROMIDE

HALOPERIDOL

DEXCLAMOL

PIPAMPERONE

CLOZAPINE

HALOPOMIDE

1-BUTACLAMOL
ACEPERO NE

1.

Time (Minutes

N

Analgesia

5 Minutes

1

35 Minutes

60

10

20

10

0.04

60

8

12

38

0.16

60

8

50

0

0.64

60

9

89

100*

0.04

60

5

40

20

0.08

60

10

90

60

0.64

60

14

79

67

2 .50

60

8

38

75

0.04

60

9

44

67

0.16

60

9

78

44

0 .64

60

8

38

38

2.50

60

10

60

40

10.00

60

7

72

86*

0 . 64

30

9

22

11

1.25

30

10

50

30

2.50

30

9

67

100*

0.16

60

11

36

36

0.64

60

10

20

40

0 .16

60

10

40

20

10.00

60

10

30

30

Analg es ic latencies exceed the group control mean by three standard
deviations or more.
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analgesic potency of cyclazocine 35 minutes after cyclazocine
administration (Table 18).

Clozapine administered alone does

not produce analgesia.
Increases in percent animals with analgesic readings were
observed following pretreatment with haloperidol (0.08, 0.64,
and 2.5 mg/kg) and dexclamol (0.16 mg/kg), but these changes
were not statistically significant (Table 18).
No change in the analgesic potency of cyclazocine was
evident following pretreatment with halopomide (0.16 and 0.64
mg/kg), 1-butaclamol (0.16 mg/kg) or aceperone (10 mg/kg).

V.

DISCUSSION

In agreement with other recent reports

(Hirschhorn, 1977;

Rosecrans et al., 1978; Teal and Holtzman, 1980), the narcotic
agonist-antagonist cyclazocine has been shown to produce a discriminative stimulus capable of controlling operant responding in the rat.

The results described indicate that these ef-

fects are specific to cyclazocine and that they are substantially, but not exclusively, based on narcotic-like actions of
cyclazocine.
The specificity of the discriminative stimulus produced
by cyclazocine is demonstrated by the dose dependent nature
of lever selection in animals trained to discriminate cyclazocine from saline.

The drug specificity of these effects is

also seen in the dose dependent nature of generalization of
the cyclazocine discriminative stimulus to other narcotic
drugs.
The discriminative stimulus produced by cyclazocine was
found to be completely blocked by the pure narcotic antagonist
naloxone, suggesting that the discriminative stimulus produced
by cyclazocine is mediated by activity at central opiate receptors.

Cyclazocine discriminative stimulus production at

central opiate receptors is also suggested by the nature of
the

sti~ulus

periments.

generalization which were observed in these exComplete generalization of the cyclazocine dis-

criminative stimulus to other narcotic drugs.

SiJ

The discriminative stimuJus produced by cyclazocine was
found to be completely blocked by the pure narcotic antagonist
naloxone, suggesting that the discriminative stimulus produced
by cyclazocine is mediated by activity at central opiate receptors.

Cyclazocine discriminative stimulus production at

central opiate receptors is also suggested by the nature of
the stimulus generalization which were observed in these experiments.

Complete generalization of the cyclazocine discrim-

inative stimulus was observed to all narcotic agonists and antagonists tested with the exception of U-49,274A and U-50,788E
while generalization testing with non-narcotic psychoactive
drugs resulted in nearly exclusive saline lever selection.
Although the central activity of cyclazocine was narcotic
in nature, certain portions of the results indicate that the
discriminative stimulus produced by cyclazocine may differ from
that produced by the pure narcotic agonist morphine. Both the
cyclazocine discriminative stimulus and the morphine . discriminative stimulus were reversed by the narcotic antagonist
naloxone.

Similarly, generalization of each of these drugs to

the other was antagonized by naloxone.

The dose of naloxone

required to antagonize the effects of cyclazocine far exceeded
that required to antagonize morphine.

A mechanism for such a

difference is not readily apparent from the present results
however it is noteworthy that a similar difference in naloxone
sensitivity between cyclazocine like drugs and morphine has
been observed in previous discriminative stimulus studies
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(Hirschhorn, 1977; Rosecrans et al., 1978; Teal and Holtzman,
1980) and animal behavior studies (Buckett and Shaw, 1975;
Tepper and Woods, 1978).
The nature in which cyclazocine and morphine generalized
to ethylketocyclazocine further suggest a difference in the
effects produced by cyclazocine and morphine.

In the case of

cyclazocine, ethylketocyclazocine generalization was a uniformly increasing dose dependent effect.

In the morphine gen-

eralization experiments, it was found that ethylketocyclazocine generalization approximated a bell shaped curbe with the
highest dose tested resulting in 100% saline lever selection.
It is apparent that the generalization to ethylketocyclazocine
by cyclazocine and morphine is different suggesting differences in central binding characteristics.
An interesting aspect of the bell shaped morphine generalization to ethylketocyclazocine is that it closely approximated the nature of the subjective effects produced in humans
by narcotic agonist-antagonist when compared to morphine.

It

has been shown that human addicts identify low doses of narcotic agonist-antagonists as morphine like while higher doses
tend to produce effects unlike morphine such as dysphoria and
hallucinations (Martin et al., 1965).
Teal and Holtzman (1980) recently showed that the generalization of cyclazocine to phencyclidine and ketamine, two nonopioid drugs, was not subject to naloxone antagonism.

The

present results indicate that the generalization of cyclazocine
to the narcotic agonist-antagonist nalorphine also is not
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completely antagonized by naloxone.

These results suggest that

a non-narcotic component of the activities of the narcotic agonist-antagonists may be partially responsible for the production of their discriminative stimuli and suggests a qualitative difference in the central effects of the pure narcotic
agonists such as morphine and the narcotic agonist-antagonists
such as cyclazocine.
Many of the observed differences between cyclazocine and
morphine may be explained in terms of a difference in af finities of these drugs for a single opiate receptor.

An alterna-

tive explanation is that the observed differences may be due
to differential activities at different types of narcotic
receptors which have recently been described (Martin et al.,
1976; Gilbert and Martin, 1976).

Within this system, morphine

and cyclazocine are proposed to have different affinities and
activities at three heterogeneous opiate

rec~ptors.

The pre-

sent results and many other results describing differences
between cyclazocine and morphine are consistent with a multireceptor theory, however, the actual existence of these receptors has not been substantiated in all species, requiring
caution in interpreting results in terms of multiple opiate
receptors.
A larqe body of literature exists describing the role of
dopamine in the central activity of narcotic analgesics (for
review see Lal, 1975).

The present results demonstrate that

dopamine also plays a role in the production of the discriminative stimulus properties of narcotic analgesics. Haloperidol,
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benperidol and d-butaclamol, neuroleptic druqs with dopamine
receptor blocking properties, all caused an attenuation of the
cyclazocine discriminative stimulus while haloperidol also
blocked the stimulus strength of morphine.

Since this effect

was observed in the stimuli produced by the pure narcotic agonist as well as the narcotic agonist-antagonists, it is
reasonable to assume that the dopamine activity which is present is common to both types of narcotic agents and is not a
predorninent factor responsible for the observed differences
between morphine and cyclazocine.
Although neuroleptic pretreatment caused a diminished
discriminative stimulus strength of cyclazocine and morphine,
neuroleptic pretreatment produced a potentiation of cyclazocine analgesia in these experiments.

Previous results (Head

et al., 1979) showed that neuroleptic pretreatment caused a
potentiation of morphine analgesia.

Again, cyclazocine and

morphine are effected in a similar fashion by neuroleptic pretreatment suggesting a similar dopamine role in the central
activities of each of these drugs.
The attenuating effects neuroleptics had upon the cyclazocine and morphine discriminative stimuli when compared with
the potentiating effects neuroleptics had upon cyclazocine and
morphine analgesia show that the discriminative

~timuli

pro-

duced by these drugs are not based upon the analgesic properties of these drugs.

If in fact the stimulus properties were

based upon analgesia, one would expect either exclusive potentiation or exclusive attenuation of these properties following
neuroleptic pretreatment.
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VI.

CONCLUSION

The experiments which have been described demonstrate
that the narcotic agonist-antagonist cyclazocine produces
a discriminative stimulus in the laboratory rat.

In light

of its naloxone reversability and qeneralization to

other

narcntic drugs, it is suggested that the cyclazocine discriminative stimulus is principally produced by activity at
central opiate receptors.

The cyclazocine discriminative

stimulus was subject to attenuation following neuroleptic
pretreatment indicating that an additional component of the
cyclazocine discriminative stimulus is

dopa~inergic

in na-

ture.
Similarities between the cyclazocine discriminative
stimulus and the discriminative stimulus produced by the
pure narcotic agonist morphine were seen in that the morphine discriminative stimulus was also subject to naloxone
antasonism and neuroleptic attenuatior..
Althoug h the cyclazocine discriwinative stimulus was
shown to be morphine like as described above, portions of
the results also indicate that the cyclazocine discriminative stimulus di f fered from th e morphine
stimulus.

discri~inative

Cyclazocine was shown to be much less sensitive

to naloxone antagonism than was morphine.

In addition,

the generalization of cyclazocine and morphine to ethylketoc y clazocine were found to differ markedly.

6'3

These experiments have also demonstrated that the cyclazocine discrininative stimulus is not based upon the analgesic
properties of the drug.

While the discriminative stimulus

was partially blocked by neuroleptic pretreatr'.ent, the analgesic properties of cyclazocine were potentiated by neuroleptic pretreatment.

In light of previous experimentation

which denonstrated that morphine analgesia was potentiated
by haloperidol (Head et al., 1979) ,the present finding of
haloperidol attenuation of the morphine discriminative stimulus indicates that the morphine discriminative stimulus is
not based upon the analgesic properties of morphine.
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